American International Group, Inc. Aerovate Therapeutics, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$17.68 - $29.57 $830 - $1,389	-47 Reduced 0.85%	5,509 $162,000
Q4 2023 Feb 13, 2024	SELL	$9.58 - $24.25 $220 - $557	-23 Reduced 0.41%	5,556 $125,000
Q3 2023 Nov 13, 2023	BUY	$12.9 - $18.88 $9,481 - $13,876	735 Added 15.17%	5,579 $75,000
Q2 2023 Aug 04, 2023	BUY	$15.63 - $22.01 $6,439 - $9,068	412 Added 9.3%	4,844 $83,000
Q1 2023 May 12, 2023	BUY	$19.17 - $27.7 $1,686 - $2,437	88 Added 2.03%	4,432 $89,000
Q4 2022 Feb 10, 2023	SELL	$15.92 - $30.52 $254 - $488	-16 Reduced 0.37%	4,344 $127,000
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $930 - $1,624	63 Added 1.47%	4,360 $72,000
Q2 2022 Aug 12, 2022	SELL	$10.8 - $16.91 $23,727 - $37,151	-2,197 Reduced 33.83%	4,297 $67,000
Q1 2022 May 13, 2022	BUY	$8.25 - $18.33 $9,405 - $20,896	1,140 Added 21.29%	6,494 $119,000
Q4 2021 Feb 11, 2022	SELL	$9.14 - $21.54 $1,471 - $3,467	-161 Reduced 2.92%	5,354 $63,000
Q3 2021 Nov 12, 2021	BUY	$11.76 - $22.49 $64,856 - $124,032	5,515 New	5,515 $116,000

28.4M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.